Barclays Cuts Certara (NASDAQ:CERT) Price Target to $12.00

Certara (NASDAQ:CERT) had its price target lowered by research analysts at Barclays from $14.00 to $12.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential upside of 9.99% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Finally, KeyCorp lowered their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Trading Up 5.8 %

Shares of NASDAQ:CERT opened at $10.91 on Thursday. Certara has a 52 week low of $9.99 and a 52 week high of $19.87. The company’s 50 day moving average is $11.10 and its two-hundred day moving average is $13.77. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.76 billion, a PE ratio of -21.82, a P/E/G ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The firm had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. During the same period in the prior year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. Equities analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Certara

A number of large investors have recently bought and sold shares of the company. Geneva Capital Management LLC raised its position in Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after buying an additional 37,392 shares during the last quarter. Clearbridge Investments LLC raised its position in Certara by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock worth $74,617,000 after buying an additional 32,846 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock valued at $38,418,000 after purchasing an additional 248,448 shares in the last quarter. Finally, Daventry Group LP increased its holdings in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.